[{"address1": "8000 Marina Boulevard", "address2": "Suite 120", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 770 0077", "website": "https://veratx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.", "fullTimeEmployees": 82, "companyOfficers": [{"maxAge": 1, "name": "Dr. Marshall W. Fordyce M.D.", "age": 49, "title": "Founder, President, CEO & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 910138, "exercisedValue": 0, "unexercisedValue": 8470996}, {"maxAge": 1, "name": "Mr. Sean P. Grant M.B.A.", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 642000, "exercisedValue": 0, "unexercisedValue": 368374}, {"maxAge": 1, "name": "Mr. David L. Johnson M.B.A.", "title": "Chief Opearating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph R. Young M.B.A.", "age": 51, "title": "Senior VP of Finance & Chief Accounting Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Allen  Ebens B.Sc., Ph.D.", "title": "Executive Vice President of Research", "fiscalYear": 2023, "totalPay": 397024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason S Carter", "title": "Chief Legal Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Rauber", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tom  Doan", "age": 52, "title": "Senior Vice President of Development Operations", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lauren  Frenz M.B.A.", "age": 39, "title": "Chief Business Officer", "yearBorn": 1985, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Julien E. Capers J.D.", "title": "Senior Vice President of Legal", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 34.18, "open": 34.25, "dayLow": 25.99, "dayHigh": 34.5, "regularMarketPreviousClose": 34.18, "regularMarketOpen": 34.25, "regularMarketDayLow": 25.99, "regularMarketDayHigh": 34.5, "beta": 1.109, "forwardPE": -9.018062, "volume": 6404451, "regularMarketVolume": 6404451, "averageVolume": 717030, "averageVolume10days": 1110170, "averageDailyVolume10Day": 1110170, "bid": 24.52, "ask": 33.66, "bidSize": 200, "askSize": 200, "marketCap": 1738852224, "fiftyTwoWeekLow": 25.99, "fiftyTwoWeekHigh": 51.61, "fiftyDayAverage": 39.626, "twoHundredDayAverage": 39.9662, "currency": "USD", "enterpriseValue": 1440452096, "floatShares": 51449347, "sharesOutstanding": 63323100, "sharesShort": 8102354, "sharesShortPriorMonth": 7153678, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.128, "heldPercentInsiders": 0.06996, "heldPercentInstitutions": 1.0924, "shortRatio": 10.97, "shortPercentOfFloat": 0.1707, "impliedSharesOutstanding": 78819400, "bookValue": 5.253, "priceToBook": 5.227489, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -134378000, "trailingEps": -2.61, "forwardEps": -3.11, "52WeekChange": -0.38554484, "SandP52WeekChange": 0.22894537, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "VERA", "underlyingSymbol": "VERA", "shortName": "Vera Therapeutics, Inc.", "longName": "Vera Therapeutics, Inc.", "firstTradeDateEpochUtc": 1620999000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "5a1186a3-379b-3559-920e-cf7bafd3a084", "messageBoardId": "finmb_683328925", "gmtOffSetMilliseconds": -18000000, "currentPrice": 27.46, "targetHighPrice": 107.0, "targetLowPrice": 25.0, "targetMeanPrice": 63.0, "targetMedianPrice": 60.0, "recommendationMean": 1.42857, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 14, "totalCash": 353308992, "totalCashPerShare": 5.579, "totalDebt": 54910000, "quickRatio": 13.426, "currentRatio": 13.759, "debtToEquity": 18.996, "returnOnAssets": -0.33372003, "returnOnEquity": -0.65111, "freeCashflow": -78348376, "operatingCashflow": -120641000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-17"}]